Logo image of WLLW.CA

WILLOW BIOSCIENCES INC (WLLW.CA) Stock Fundamental Analysis

TSX:WLLW - CA97111B4047 - Common Stock

0.155 CAD
-0.01 (-3.12%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

1

WLLW gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. WLLW may be in some trouble as it scores bad on both profitability and health. WLLW is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year WLLW has reported negative net income.
WLLW had a negative operating cash flow in the past year.
In the past 5 years WLLW always reported negative net income.
WLLW had a negative operating cash flow in each of the past 5 years.
WLLW.CA Yearly Net Income VS EBIT VS OCF VS FCFWLLW.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

WLLW has a Return On Assets (-179.33%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -179.33%
ROE N/A
ROIC N/A
ROA(3y)-175.17%
ROA(5y)-139.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WLLW.CA Yearly ROA, ROE, ROICWLLW.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for WLLW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WLLW.CA Yearly Profit, Operating, Gross MarginsWLLW.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

1

2. Health

2.1 Basic Checks

WLLW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, WLLW has more shares outstanding
Compared to 5 years ago, WLLW has more shares outstanding
Compared to 1 year ago, WLLW has a worse debt to assets ratio.
WLLW.CA Yearly Shares OutstandingWLLW.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
WLLW.CA Yearly Total Debt VS Total AssetsWLLW.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -59.82, we must say that WLLW is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -59.82, WLLW is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -59.82
ROIC/WACCN/A
WACC9.08%
WLLW.CA Yearly LT Debt VS Equity VS FCFWLLW.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.01 indicates that WLLW should not have too much problems paying its short term obligations.
With a Current ratio value of 1.01, WLLW perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
WLLW has a Quick Ratio of 1.01. This is a normal value and indicates that WLLW is financially healthy and should not expect problems in meeting its short term obligations.
WLLW has a Quick ratio (1.01) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
WLLW.CA Yearly Current Assets VS Current LiabilitesWLLW.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.95% over the past year.
The Revenue has grown by 570.53% in the past year. This is a very strong growth!
WLLW shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 229.77% yearly.
EPS 1Y (TTM)66.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
Revenue 1Y (TTM)570.53%
Revenue growth 3Y229.77%
Revenue growth 5YN/A
Sales Q2Q%3349.02%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WLLW.CA Yearly Revenue VS EstimatesWLLW.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 1M 2M 3M 4M
WLLW.CA Yearly EPS VS EstimatesWLLW.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

WLLW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WLLW.CA Price Earnings VS Forward Price EarningsWLLW.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WLLW.CA Per share dataWLLW.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

WLLW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WILLOW BIOSCIENCES INC

TSX:WLLW (9/4/2025, 7:00:00 PM)

0.155

-0.01 (-3.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-10 2025-11-10
Inst Owners0.1%
Inst Owner ChangeN/A
Ins Owners2.66%
Ins Owner ChangeN/A
Market Cap97.56M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -179.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-175.17%
ROA(5y)-139.67%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2.75
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -59.82
F-Score4
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)20.3%
Cap/Depr(5y)29.57%
Cap/Sales(3y)45.39%
Cap/Sales(5y)2299.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)570.53%
Revenue growth 3Y229.77%
Revenue growth 5YN/A
Sales Q2Q%3349.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y71.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.21%
OCF growth 3YN/A
OCF growth 5YN/A